ライフサイエンスコーパス: cord blood transplantation

1 imilar to those achieved following umbilical cord blood transplantation.

2 CD34(+)/CD38(-)/CD90(+)/CD45RA(+) HSCs after cord blood transplantation.

3 leted bone marrow or unmanipulated umbilical cord blood transplantation.

4 s may have clinical application in marrow or cord blood transplantation.

5 ion for non-malignant diseases-for umbilical cord blood transplantation.

6 given single-unit, unrelated donor umbilical cord blood transplantation.

7 gressed to phase 1 clinical trials in double cord blood transplantation.

8 d the delayed platelet engraftment following cord blood transplantation.

9 eformed DSAs on outcomes in double umbilical cord blood transplantation.

10 ot been well defined for unrelated umbilical-cord blood transplantation.

11 alignancies undergoing unrelated double unit cord blood transplantation.

12 with the Rac2 mutation underwent successful cord blood transplantation.

13 t after autologous, allogeneic and umbilical cord blood transplantation.

14 hromatic leukodystrophy treated by umbilical cord blood transplantation.

15 chronic myelogenous leukemia after umbilical cord blood transplantation.

16 phoid recovery are the 2 major challenges in cord blood transplantation.

17 to increasing homing and engraftment during cord blood transplantation.

18 nt and survival in unrelated donor umbilical cord blood transplantation.

19 nd have the potential for immunotherapy post cord blood transplantation.

20 doses restricts the usefulness of umbilical-cord-blood transplantation.

21 interaction on leukaemia-free survival after cord-blood transplantation.

22 chronic GVHD was more likely to occur after cord-blood transplantation.

23 delay of functional B cells associated with cord blood transplantations.

24 (111 patients) or single-unit (113 patients) cord-blood transplantation after a uniform myeloablative

25 rine model for human placental and umbilical cord blood transplantation and second to evaluate the en

26 nts with Hurler syndrome underwent umbilical cord blood transplantation and were evaluated at baselin

27 e marrow failure that occurs after umbilical cord blood transplantation and with aplastic anemia, res

28 rved in the setting of immune recovery after cord blood transplantation, and may be associated with i

29 ntions, such as hydroxyurea; bone marrow and cord blood transplantation; and improvements in supporti

30 Two critical concerns in clinical cord blood transplantation are the initial time to engra

31 chromatic leukodystrophy underwent umbilical cord blood transplantation at different stages of diseas

32 There were no differences in outcome after cord-blood transplantation between patients with one HLA

33 ce graft-versus-host disease after umbilical cord blood transplantation, but this naivety and their l

34 uence NK cell reconstitution after umbilical cord blood transplantation by accelerating the different

35 Hematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedur

36 Dramatic advances in cord blood transplantation (CBT) have been made in the p

37 ective study of T-cell immune recovery after cord blood transplantation (CBT) in a predominantly adul

38 While cord blood transplantation (CBT) is an effective therapy

39 Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result fr

40 summarizes the current status of double-unit cord blood transplantation (CBT) to improve engraftment,

41 The ability of cord blood transplantation (CBT) to prevent relapse depe

42 Unrelated cord blood transplantation (CBT) without in vivo T-cell

43 In cord blood transplantation (CBT), donor-directed host an

44 Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defec

45 of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT r

46 d with improved outcomes following pediatric cord blood transplantation (CBT).

47 maternal HLA antigens (NIMA) and double-unit cord blood transplantation (CBT).

48 it in 14 patients who received a double-unit cord blood transplantation (CBT).

49 isease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow

50 eneic cell transplantation [ACT]; n = 18) or cord blood transplantation (CBT; n = 16).

51 immune response on outcomes after unrelated cord blood transplantations (CBTs).

52 Double-unit cord blood transplantation (DCBT) appears to enhance eng

53 In adults, umbilical cord blood transplantation, double umbilical cord blood

54 Although double umbilical cord blood transplantation (dUCBT) in adult patients may

55 reactivity is favored after double umbilical cord blood transplantation (dUCBT) in which cord blood (

56 Cord-blood transplantation favorably altered the natural

57 od grafts can be used as an animal model for cord blood transplantation for gene therapy studies wher

58 atching who received a single unit umbilical cord blood transplantation for non-malignant diseases re

59 HLA matching on outcomes of single umbilical-cord blood transplantations for leukaemia and myelodyspl

60 h hematological malignancies given umbilical cord blood transplantation from donors carrying a homozy

61 Unrelated donor cord blood transplantation from partially HLA-mismatched

62 Umbilical cord blood transplantation from unrelated donors has bee

63 transplant-related mortality after umbilical-cord-blood transplantation, greater investment in large-

64 Although cord blood transplantation has significantly extended th

65 n of clinically effective therapies, such as cord blood transplantation, has been impeded because of

66 The results for adult umbilical cord blood transplantation have improved, with greater e

67 ents undergoing T-cell-depleted or unrelated cord blood transplantation have undetectable EBV-specifi

68 More than 4000 cord blood transplantations have been performed worldwid

69 re similar after single-unit and double-unit cord-blood transplantation; however, a single-unit cord-

70 Outcomes of unrelated donor cord blood transplantation in 191 hematologic malignancy

71 e the first report of a successful umbilical cord blood transplantation in 1988, there has been great

72 Data regarding the outcome of cord-blood transplantation in adults are scant, despite

73 Umbilical cord blood transplantation is associated with durable en

74 Cord blood transplantation is now an established field w

75 A major area of concern for the use of cord blood transplantation is the delay in myeloid and l

76 unger age, total body irradiation, umbilical cord blood transplantation, lymphocyte count <100/mm3, H

77 Umbilical cord blood transplantation may cure a relevant proportio

78 studies suggested that allogeneic umbilical cord blood transplantation may potentially emerge as the

79 tigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regen

80 In cord blood transplantation, optimal unit selection requi

81 cyte antigen-matched sibling donor umbilical cord blood transplantation, or 0-2 human leukocyte antig

82 sociated with HHV-6 DNAemia were as follows: cord blood transplantation (P<0.001), conditioning regim

83 The literature shows that after umbilical cord blood transplantation the relapse rate, disease-fre

84 In umbilical cord blood transplantation, the ability to find adequate

85 HHV-6B) commonly reactivates after umbilical cord blood transplantation (UCBT) and is associated with

86 ntation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable treatment

87 (n = 226) or double-unit (n = 435) unrelated cord blood transplantation (UCBT) following a reduced-in

88 f the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the treatment of h

89 Umbilical cord blood transplantation (UCBT) is an expanding practi

90 Unrelated cord blood transplantation (UCBT) is associated with del

91 Umbilical cord blood transplantation (UCBT) is increasingly used a

92 A disadvantage of umbilical cord blood transplantation (UCBT) is the delay in immune

93 omidubicel compared with standard umbilical cord blood transplantation (UCBT).

94 stitution observed after unrelated umbilical cord blood transplantation (UCBT).

95 morbidity and mortality following umbilical cord blood transplantation (UCBT).

96 variella volvacea following double umbilical cord blood transplantation (UCBT).

97 GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT).

98 ctive single-center analysis of 50 umbilical cord blood transplantations UCBTs performed from 2001 to

99 including 37 single and 13 double umbilical cord blood transplantations UCBTs.

100 engraftment after unrelated donor umbilical cord blood transplantation was 100% with no patient havi

101 Initially, umbilical cord blood transplantation was limited to children, give

102 w outlines the state of the art of umbilical cord blood transplantation, with emphasis on practical c